Erdle Stephanie C, Cook Victoria E, Cameron Scott B, Yeung Joanne, Kapur Sandeep, McHenry Mary, Chan Edmond S, Mak Raymond, Rex Gregory A, Wong Tiffany, Soller Lianne
Division of Allergy and Immunology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, British Columbia, Canada.
Division of Allergy and Immunology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, British Columbia, Canada; Community Allergy Clinic, Victoria, British Columbia, Canada.
J Allergy Clin Immunol Pract. 2023 Apr;11(4):1177-1183. doi: 10.1016/j.jaip.2023.01.031. Epub 2023 Feb 1.
Our group previously described preschool peanut oral immunotherapy (OIT) in a real-world, multicenter setting, suggesting that this therapy is safe for most preschoolers.
To examine the safety and tolerability of tree nut (TN) OIT in preschoolers in the real world.
As part of a Canada-wide quality improvement project, TN-OIT (cashew/pistachio, walnut/pecan, hazelnut, almond, and macadamia nut) was performed in preschoolers who had (1) a skin prick test wheal diameter greater than or equal to 3 mm or a specific IgE level greater than or equal to 0.35 kU/L and a convincing objective IgE-mediated reaction or (2) no ingestion history and a specific IgE level greater than or equal to 5 kU/L. Dose escalations were performed every 2 to 4 weeks till a maintenance dose of 300 mg of TN protein was reached. Symptoms were recorded and classified using the modified World Allergy Organization Subcutaneous Immunotherapy Reaction Grading System (1, mildest; 5, fatal).
Of the 92 patients who started TN-OIT from 2018 to 2021, 79 (85.9%) underwent single-food TN-OIT and 13 (14.1%) underwent multifood TN-OIT to 2 (10.8%) or 3 (3.3%) TNs. Eighty-nine (96.7%) patients reached maintenance, and 4 (4.3%) dropped out. Sixty-five (70.7%) patients experienced reactions during buildup: 35 (38.0%) grade 1 reactions, 30 (32.6%) grade 2 reactions, no grade 3 or 4 reactions, and 2 (2.17%) received epinephrine.
Preschool TN-OIT in a real-world, multicenter setting appears safe and tolerable, with results comparable with our previously reported peanut OIT findings.
我们的研究小组之前在真实世界的多中心环境中描述了学龄前儿童花生口服免疫疗法(OIT),表明这种疗法对大多数学龄前儿童是安全的。
在现实世界中研究学龄前儿童坚果(TN)口服免疫疗法的安全性和耐受性。
作为一项全加拿大质量改进项目的一部分,对符合以下条件的学龄前儿童进行了TN-OIT(腰果/开心果、核桃/山核桃、榛子、杏仁和澳洲坚果):(1)皮肤点刺试验风团直径大于或等于3毫米或特异性IgE水平大于或等于0.35 kU/L,且有明确的客观IgE介导反应;或(2)无摄入史且特异性IgE水平大于或等于5 kU/L。每2至4周进行一次剂量递增,直至达到300毫克TN蛋白的维持剂量。使用改良的世界变态反应组织皮下免疫疗法反应分级系统记录并分类症状(1级为最轻;5级为致命)。
在2018年至2021年开始TN-OIT的92例患者中,79例(85.9%)接受了单一食物TN-OIT,13例(14.1%)接受了多种食物TN-OIT,涉及2种(10.8%)或3种(3.3%)TN。89例(96.7%)患者达到维持剂量,4例(4.3%)退出。65例(70.7%)患者在剂量递增期间出现反应:35例(38.0%)为1级反应,30例(32.6%)为2级反应,无3级或4级反应,2例(2.17%)接受了肾上腺素治疗。
在真实世界的多中心环境中,学龄前儿童TN-OIT似乎是安全且可耐受的,其结果与我们之前报道的花生OIT结果相当。